BlackRock holds 7.5% stake in Iovance Biotherapeutics

BlackRock, Inc. reports a significant ownership position in IOVANCE BIOTHERAPEUTICS, INC. common stock.

Rhea-AI Filing Summary

BlackRock, Inc. reports a significant ownership position in IOVANCE BIOTHERAPEUTICS, INC. common stock. As of June 30, 2026, BlackRock and certain reporting business units beneficially owned 33,366,587 shares, representing 7.5% of the outstanding common stock. BlackRock has sole voting power over 32,842,318 shares and sole dispositive power over 33,366,587 shares, with no shared voting or dispositive power. The shares are held on behalf of various underlying clients, and no single underlying person is stated to have more than five percent of Iovance’s total outstanding common shares.

Key Figures

Shares beneficially owned: 33,366,587 shares Percent of class: 7.5% Sole voting power: 32,842,318 shares +3 more

6 metrics

Shares beneficially owned 33,366,587 shares Common stock of IOVANCE BIOTHERAPEUTICS, INC. beneficially owned by BlackRock as of June 30, 2026

Percent of class 7.5% Portion of Iovance common stock class beneficially owned by BlackRock

Sole voting power 32,842,318 shares Shares of Iovance common stock over which BlackRock has sole power to vote

Sole dispositive power 33,366,587 shares Shares over which BlackRock has sole power to dispose or direct disposition

Amendment number Amendment No. 3 Amendment number of the Schedule 13G/A reporting this ownership

Signature date 07/28/2026 Date the Schedule 13G/A was signed by the Managing Director

Key Terms

beneficially owned, sole voting power, sole dispositive power, Schedule 13G, +1 more

5 terms

beneficially owned regulatory

"this reflects the securities beneficially owned, or deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 32,842,318.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 33,366,587.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"If a parent holding company has filed this schedule, pursuant to"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

parent holding company regulatory

"If a parent holding company has filed this schedule, pursuant to"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of IOVA does BlackRock currently own according to this Schedule 13G/A?

BlackRock reports beneficial ownership of 7.5% of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) common stock, representing 33,366,587 shares. This reflects holdings of certain BlackRock business units aggregated under SEC beneficial ownership rules.

How many IOVA shares does BlackRock report as beneficially owned?

BlackRock reports 33,366,587 IOVANCE BIOTHERAPEUTICS, INC. (IOVA) common shares as beneficially owned. This total corresponds to the same number of shares over which BlackRock has sole dispositive power.

What voting power does BlackRock have over its IOVA holdings?

BlackRock has sole voting power over 32,842,318 IOVANCE BIOTHERAPEUTICS, INC. (IOVA) shares and no shared voting power. This means voting decisions for those shares are controlled by BlackRock’s reporting business units.

Does any single BlackRock client hold more than 5% of IOVA shares?

No. The filing states that various persons have rights to dividends or sale proceeds for the IOVA shares, but no one person’s interest exceeds five percent of Iovance’s total outstanding common shares.

Which entity is listed as the reporting owner of the IOVA shares?

The reporting owner is BlackRock, Inc., a Delaware corporation. The filing aggregates securities beneficially owned by specified Reporting Business Units of BlackRock and its subsidiaries and affiliates, excluding disaggregated units under SEC Release No. 34-39538.

What kind of power does BlackRock report over the disposition of IOVA shares?

BlackRock reports sole dispositive power over 33,366,587 IOVANCE (IOVA) shares and no shared dispositive power. Sole dispositive power means BlackRock can direct how these shares are sold or transferred, subject to client arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 04:47 PM Accepted by SEC EDGAR 07/28/2026 - 04:44 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

IOVANCE BIOTHERAPEUTICS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

462260100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 462260100

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 32,842,318.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 33,366,587.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

33,366,587.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.5 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IOVANCE BIOTHERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 825 Industrial Road, Suite 100 SAN CARLOS CA 94070
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 462260100
Item 4.	Ownership
(a)	Amount beneficially owned: 33366587
(b)	Percent of class: 7.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 32842318
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 33366587
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of IOVANCE BIOTHERAPEUTICS, INC.. No one person's interest in the common stock of IOVANCE BIOTHERAPEUTICS, INC. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/28/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7